News
Evolva and Lallemand close the sale of Evolva AG to Danstar Ferment AG on 28 December 2023
Form 8.3 - The Vanguard Group, Inc.: Dechra Pharmaceuticals plc
Vistagen Receives Notice from European Patent Office of Intention to Grant Patent for AV-101 to Treat Neuropathic Pain
Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression, and other central nervous
Novocure to Participate in 42nd Annual J.P. Morgan Healthcare Conference
Novocure (NASDAQ: NVCR) announced today that management will participate in the 42nd Annual J.P. Morgan Healthcare Conference on January 9-10, 2024. William Doyle, Novocure’s Executive Chairman
EQS-News: Formycon announces EMA acceptance of the MAA for FYB203, a biosimilar candidate to Eylea® (Aflibercept)
Kuros Biosciences Announces Results from Two Prospective Randomized Clinical Trials: STRUCTURE and MAXA
Form 8.3 - The Vanguard Group, Inc.: Dechra Pharmaceuticals plc
Form 8.3 - The Vanguard Group, Inc.: Dechra Pharmaceuticals plc
QuidelOrtho to Present at 42nd Annual J.P. Morgan Healthcare Conference
QuidelOrtho Corporation (NASDAQ:QDEL) (“QuidelOrtho”), a global provider of innovative in vitro diagnostics technologies designed for point-of-care settings, clinical labs and transfusion medicine
Poxel Provides Corporate Update
Regulatory News:
POXEL SA (Euronext: POXEL - FR0012432516) (Paris:POXEL), a clinical stage biopharmaceutical company developing innovative treatments for chronic serious diseases with metabolic
Transgene Announces Upcoming Investor Meetings
Regulatory News:
TRANSGENE (Paris:TNG) today announces that Management will participate in several investor events in the upcoming investor events, as set out below.
Transgene will meet
Shareholders approve the sale of Evolva AG to Lallemand Inc. Swiss subsidiary at extraordinary general meeting
Savara Introduces aPAP ClearPath™, a GM-CSF Autoantibody Blood Test to Detect Autoimmune Pulmonary Alveolar Proteinosis (aPAP)
Savara Inc. (Nasdaq: SVRA) (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, recently launched aPAP ClearPath™, a new serum-based blood test that can
Form 8.3 - The Vanguard Group, Inc.: Dechra Pharmaceuticals PLC
Sensorion Publishes Results of Combined General Meeting Resolutions
Regulatory News:
Sensorion (FR0012596468 – ALSEN) (Paris:ALSEN) a pioneering clinical-stage biotechnology company which specializes in the development of novel therapies to restore, treat and
QuidelOrtho Receives 510(K) Clearance for Savanna® Multiplex Molecular Platform and Savanna® HSV 1+2/VZV PCR Assay
QuidelOrtho Corporation (Nasdaq: QDEL) (“QuidelOrtho”), a global provider of innovative in vitro diagnostic technologies designed for point-of-care settings, clinical labs and transfusion medicine
Agilent Makes Strategic Updates to Organizational Structure
Agilent Technologies Inc. (NYSE: A) today announced it has moved the company’s Cell Analysis Division into its Diagnostics and Genomics Group (DGG) as part of a strategy to further strengthen
Savara Added to the NASDAQ Biotechnology Index
Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced that the company was added to the NASDAQ Biotech Index (Nasdaq: NBI)
Simulations Plus Announces First Quarter Fiscal Year 2024 Earnings and Conference Call Date
Simulations Plus, Inc. (Nasdaq: SLP) (“Simulations Plus”), announced today that it will report first quarter fiscal 2024 financial results after the market close on Wednesday, January 3, 2024.
Form 8.3 - The Vanguard Group, Inc.: Dechra Pharmaceuticals PLC
Aurinia Submits IND Application to US Food & Drug Administration for AUR 200
Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (Aurinia or the Company) – Aurinia announced today the submission of its Investigational New Drug application (IND) to the U.S. Food and Drug
Pfizer Invites Public to View and Listen to Webcast of January 30 Conference Call with Analysts
Pfizer Inc. (NYSE: PFE) invites investors and the general public to view and listen to a webcast of a conference call with investment analysts at 10 a.m. EST on Tuesday, January 30, 2024. The
Dexcom to Present at 42nd Annual J.P. Morgan Healthcare Conference
DexCom, Inc. (NASDAQ:DXCM) today announced that Kevin Sayer, Chairman, President and Chief Executive Officer, will present an update on the company at the 42nd annual J.P. Morgan Healthcare
Form 8.3 - The Vanguard Group, Inc.: Dechra Pharmaceuticals PLC
Chemed Corporation Announces the Appointment of Michael D. Witzeman as CFO
Chemed Corporation (NYSE: CHE) – Today Chemed Corporation’s Board of Directors has appointed Michael D. Witzeman as Chief Financial Officer, effective January 1, 2024, following the retirement of